share_log

復星醫藥：海外監管公告 - 中國國際金融股份有限公司關於上海復星醫藥（集團）股份有限公司非公開發行A股股票持續督導保薦總結報告書

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 12 17:58
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月12日發布海外監管公告，公告中提及該公司在上海證券交易所非公開發行A股股票的持續督導保薦總結報告書。該非公開發行於2022年7月完成，共發行106,756,666股，募集資金總額達人民幣448,378萬元。扣除發行費用後，實際募集資金淨額為人民幣445,619.87萬元。中金公司擔任保薦機構，並於2023年12月31日結束其持續督導期。報告中指出，復星醫藥在募集資金使用、信息披露、內部控制等方面均符合規定，並無重大事項發生。截至2023年12月31日，已使用募集資金人民幣367,137.85萬元，剩餘資金將繼續按計劃使用，中金公司將持續履行督導職責。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月12日發布海外監管公告，公告中提及該公司在上海證券交易所非公開發行A股股票的持續督導保薦總結報告書。該非公開發行於2022年7月完成，共發行106,756,666股，募集資金總額達人民幣448,378萬元。扣除發行費用後，實際募集資金淨額為人民幣445,619.87萬元。中金公司擔任保薦機構，並於2023年12月31日結束其持續督導期。報告中指出，復星醫藥在募集資金使用、信息披露、內部控制等方面均符合規定，並無重大事項發生。截至2023年12月31日，已使用募集資金人民幣367,137.85萬元，剩餘資金將繼續按計劃使用，中金公司將持續履行督導職責。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 12, 2024, MENTIONING THE SUMMARY REPORT OF THE COMPANY'S CONTINUING SUPERVISORY RECOMMENDATION FOR NON-PUBLIC ISSUANCE OF A SHARES ON THE SHANGHAI STOCK EXCHANGE. The IPO was completed in July 2022 with a total of 106,756,666 shares for a total raising of RMB448,378 million. Net fundraising was RMB445,619.87 million after deducting the issuance costs. The JSC acts as a sponsor and ends its continuous supervision period on 31 December 2023. The report states that Fustar Pharmaceuticals complies with the requirements in terms of fundraising use, information disclosure, internal control, etc., and no significant events have occurred. As of December 31, 2023, RMB 367,137.85 million has been used to raise funds. The remaining funds will continue to be used as planned, and the JSC will continue to fulfill its supervisory duties.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED AN OVERSEAS REGULATORY NOTICE ON APRIL 12, 2024, MENTIONING THE SUMMARY REPORT OF THE COMPANY'S CONTINUING SUPERVISORY RECOMMENDATION FOR NON-PUBLIC ISSUANCE OF A SHARES ON THE SHANGHAI STOCK EXCHANGE. The IPO was completed in July 2022 with a total of 106,756,666 shares for a total raising of RMB448,378 million. Net fundraising was RMB445,619.87 million after deducting the issuance costs. The JSC acts as a sponsor and ends its continuous supervision period on 31 December 2023. The report states that Fustar Pharmaceuticals complies with the requirements in terms of fundraising use, information disclosure, internal control, etc., and no significant events have occurred. As of December 31, 2023, RMB 367,137.85 million has been used to raise funds. The remaining funds will continue to be used as planned, and the JSC will continue to fulfill its supervisory duties.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.